Xinghuo Li

Xinghuo Li, Ph.D., is an Associate at Frazier Life Sciences, a venture capital firm focused on investments in the life sciences sector, particularly in biotechnology and novel therapeutics. As part of the investment team based in California, Dr. Li is responsible for sourcing, evaluating, and executing investments in companies developing innovative treatments and biopharmaceutical products. His role centers on identifying growth opportunities and supporting portfolio companies that are at the forefront of disease treatment and healthcare innovation.

Prior to joining Frazier Life Sciences in 2024, Dr. Li was an Associate at McKinsey & Company, where he worked from 2020 to 2024, advising clients in the pharmaceutical and healthcare industries on strategic, operational, and commercial challenges. His extensive consulting experience provided him with deep insights into the life sciences ecosystem, assisting clients with product development, market access, and business strategy.

Dr. Li holds a Ph.D. in immunotherapy from Weill Cornell Graduate School of Medical Sciences and a Bachelor's degree in Pharmaceutical Sciences from Peking University. His research expertise in immunotherapy and pharmaceuticals informs his investment focus, with a particular emphasis on biotechnology, drug development platforms, and transformative therapeutic modalities. At Frazier, he leverages both his scientific background and industry experience to enable successful investments in cutting-edge biopharma ventures.